Moleculin Biotech is trading 5.02% down at $0.50 on September 30, 2026, with no company-specific announcement found to explain the decline. - The latest major update, released September 29, said enrollment in Part A of the pivotal MIRACLE trial was complete, with 89 subjects enrolled and a Q1 2027 data readout expected; it does not establish the cause of the drop. - The Nasdaq and S&P 500 were higher, so the broader market context does not clearly explain the decline. - No volume information was provided.